{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:41:18Z","timestamp":1792784478318,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Silvo O. Conte Center","award":["P50MH094268"],"award-info":[{"award-number":["P50MH094268"]}]}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.schres.2017.06.027","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T23:16:03Z","timestamp":1497914163000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia"],"prefix":"10.1016","volume":"193","author":[{"given":"Ming Teng","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Rosenzweig-Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5074","key":"10.1016\/j.schres.2017.06.027_bb0005","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1126\/science.1519064","article-title":"SV2, a brain synaptic vesicle protein homologous to bacterial transporters","volume":"257","author":"Bajjalieh","year":"1992","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.neuron.2012.03.023","article-title":"Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment","volume":"74","author":"Bakker","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2017.06.027_bb0015","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.nicl.2015.02.009","article-title":"Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance","volume":"7","author":"Bakker","year":"2015","journal-title":"Neuroimage Clin."},{"issue":"4","key":"10.1016\/j.schres.2017.06.027_bb0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1523\/JNEUROSCI.4521-08.2009","article-title":"SV2 renders primed synaptic vesicles competent for Ca2+-induced exocytosis","volume":"29","author":"Chang","year":"2009","journal-title":"J. Neurosci."},{"issue":"4\u20135","key":"10.1016\/j.schres.2017.06.027_bb0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0028-3908(98)00032-X","article-title":"A re-examination of the role of basal forebrain cholinergic neurons in spatial working memory","volume":"37","author":"Chappell","year":"1998","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.schres.2017.06.027_bb0030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1176\/appi.ajp.2016.16010025","article-title":"Pathological basis for deficient excitatory drive to cortical parvalbumin interneurons in schizophrenia","volume":"173","author":"Chung","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2017.06.027_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psychres.2014.07.067","article-title":"Neurocognition in schizophrenia: from prodrome to multi-episode illness","volume":"220","author":"Corigliano","year":"2014","journal-title":"Psychiatry Res."},{"issue":"26","key":"10.1016\/j.schres.2017.06.027_bb0040","doi-asserted-by":"crossref","first-page":"15268","DOI":"10.1073\/pnas.96.26.15268","article-title":"Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)","volume":"96","author":"Crowder","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.schres.2017.06.027_bb0045","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1523\/JNEUROSCI.2699-05.2006","article-title":"Synaptic vesicle protein 2 enhances release probability at quiescent synapses","volume":"26","author":"Custer","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2017.06.027_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.nlm.2013.02.001","article-title":"Effects of levetiracetam, an antiepileptic drug, on memory impairments associated with aging and Alzheimer's disease in mice","volume":"102","author":"Devi","year":"2013","journal-title":"Neurobiol. Learn. Mem."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.06.027_bb0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2007.03.013","article-title":"Neurocognitive deficits in the (putative) prodrome and first episode of psychosis","volume":"93","author":"Eastvold","year":"2007","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2017.06.027_bb0060","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.pnpbp.2009.03.013","article-title":"Disruptions in spatial working memory, but not short-term memory, induced by repeated ketamine exposure","volume":"33","author":"Enomoto","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2017.06.027_bb0065","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.biopsych.2017.03.005","article-title":"Searching for cross-diagnostic convergence: neural mechanisms governing excitation and inhibition balance in schizophrenia and autism spectrum disorders","volume":"81","author":"Foss-Feig","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"31","key":"10.1016\/j.schres.2017.06.027_bb0070","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.2174\/1381612819666131216114612","article-title":"The role of \u03b15 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia","volume":"20","author":"Gill","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"9","key":"10.1016\/j.schres.2017.06.027_bb0075","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/npp.2011.76","article-title":"A novel \u03b15GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia","volume":"36","author":"Gill","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0080","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.neuropharm.2011.05.011","article-title":"Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia","volume":"62","author":"Grace","year":"2012","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.06.027_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","article-title":"Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS","volume":"72","author":"Green","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.06.027_bb0095","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.neurobiolaging.2016.12.021","article-title":"Heightened cortical excitability in aged rodents with memory impairment","volume":"54","author":"Haberman","year":"2017","journal-title":"Neurobiol. Aging"},{"issue":"15","key":"10.1016\/j.schres.2017.06.027_bb0100","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1523\/JNEUROSCI.2552-14.2015","article-title":"Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease","volume":"35","author":"Hall","year":"2015","journal-title":"J. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.06.027_bb0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2014.09.041","article-title":"GABAergic mechanisms of hippocampal hyperactivity in schizophrenia","volume":"167","author":"Heckers","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2017.06.027_bb0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1037\/a0016791","article-title":"Course of neurocognitive deficits in the prodrome and first episode of schizophrenia","volume":"24","author":"Jahshan","year":"2010","journal-title":"Neuropsychology"},{"issue":"4","key":"10.1016\/j.schres.2017.06.027_bb0115","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/npp.2009.207","article-title":"Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment","volume":"35","author":"Koh","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2017.06.027_bb0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuropharm.2012.06.023","article-title":"Selective GABA(A) \u03b15 positive allosteric modulators improve cognitive function in aged rats with memory impairment","volume":"64","author":"Koh","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.06.027_bb0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.schres.2016.01.023","article-title":"Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia","volume":"171","author":"Koh","year":"2016","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.06.027_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.schres.2011.06.007","article-title":"Hippocampal interneurons are abnormal in schizophrenia","volume":"131","author":"Konradi","year":"2011","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2017.06.027_bb0135","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.biopsych.2017.01.004","article-title":"Impaired tuning of neural ensembles and the pathophysiology of schizophrenia: a translational and computational neuroscience perspective","volume":"81","author":"Krystal","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.06.027_bb0140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1176\/appi.ajp.2014.14010123","article-title":"Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia","volume":"172","author":"Li","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"42","key":"10.1016\/j.schres.2017.06.027_bb0145","doi-asserted-by":"crossref","first-page":"11424","DOI":"10.1523\/JNEUROSCI.2847-07.2007","article-title":"Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia","volume":"27","author":"Lodge","year":"2007","journal-title":"J. Neurosci."},{"issue":"26","key":"10.1016\/j.schres.2017.06.027_bb0150","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.schres.2017.06.027_bb0155","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.schres.2017.06.027_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0006-3223(98)00306-0","article-title":"SPECT study of visual fixation in schizophrenia and comparison subjects","volume":"46","author":"Malaspina","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-2999(03)01563-2","article-title":"Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats","volume":"466","author":"Margineanu","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.06.027_bb0170","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/hipo.1070","article-title":"Probing the human hippocampus using rCBF: contrasts in schizophrenia","volume":"11","author":"Medoff","year":"2001","journal-title":"Hippocampus"},{"issue":"2","key":"10.1016\/j.schres.2017.06.027_bb0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpsychires.2004.06.008","article-title":"Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity","volume":"39","author":"Molina","year":"2005","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.biopsych.2006.01.003","article-title":"A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia","volume":"60","author":"Moore","year":"2006","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0185","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.schres.2017.06.027_bb0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","article-title":"The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes","volume":"286","author":"Noyer","year":"1995","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.schres.2017.06.027_bb0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4088\/JCP.13065su1.06","article-title":"The early longitudinal course of cognitive deficits in schizophrenia","volume":"75","author":"Nuechterlein","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.06.027_bb0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.06.027_bb0205","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0006-8993(82)91200-8","article-title":"A disconnection analysis of hippocampal function","volume":"233","author":"Olton","year":"1982","journal-title":"Brain Res."},{"issue":"12","key":"10.1016\/j.schres.2017.06.027_bb0210","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","article-title":"Network abnormalities and interneuron dysfunction in Alzheimer disease","volume":"17","author":"Palop","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"42","key":"10.1016\/j.schres.2017.06.027_bb0215","doi-asserted-by":"crossref","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0220","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.neuropharm.2011.08.005","article-title":"Alterations in hippocampal excitability, synaptic transmission and synaptic plasticity in a neurodevelopmental model of schizophrenia","volume":"62","author":"Sanderson","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2017.06.027_bb0225","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.nlm.2013.05.007","article-title":"Hippocampal activation during the recall of remote spatial memories in radial maze tasks","volume":"106","author":"Schlesiger","year":"2013","journal-title":"Neurobiol. Learn. Mem."},{"issue":"9","key":"10.1016\/j.schres.2017.06.027_bb0230","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archgenpsychiatry.2009.115","article-title":"Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders","volume":"66","author":"Schobel","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.06.027_bb0235","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","article-title":"Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver","volume":"78","author":"Schobel","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2017.06.027_bb0240","article-title":"The antiepileptic drug levetiracetam improves auditory gating in DBA\/2 mice","volume":"1","author":"Smucny","year":"2015","journal-title":"NPJ Schizophr."},{"issue":"15","key":"10.1016\/j.schres.2017.06.027_bb0245","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1002\/cne.23367","article-title":"Hilar interneuron vulnerability distinguishes aged rats with memory impairment","volume":"521","author":"Spiegel","year":"2013","journal-title":"J. Comp. Neurol."},{"issue":"5","key":"10.1016\/j.schres.2017.06.027_bb0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nn.3356","article-title":"Physiologic brain activity causes DNA double-strand breaks in neurons, with exacerbation by amyloid-\u03b2","volume":"16","author":"Suberbielle","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.schres.2017.06.027_bb0255","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nicl.2014.07.004","article-title":"Increased hippocampal CA1 cerebral blood volume in schizophrenia","volume":"5","author":"Talati","year":"2014","journal-title":"Neuroimage Clin."},{"issue":"10","key":"10.1016\/j.schres.2017.06.027_bb0260","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1176\/appi.ajp.2010.09081187","article-title":"The hippocampal formation in schizophrenia","volume":"167","author":"Tamminga","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0265","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.biopsych.2004.10.019","article-title":"Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains","volume":"57","author":"Torrey","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.06.027_bb0270","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ajp.2013.13070981","article-title":"Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia","volume":"171","author":"Tregellas","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.06.027_bb0275","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0893-133X(01)00261-5","article-title":"Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects","volume":"25","author":"Wadenberg","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.schres.2017.06.027_bb0280","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.seizure.2009.07.004","article-title":"Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission","volume":"18","author":"Yang","year":"2009","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.schres.2017.06.027_bb0285","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1528-1167.2006.01132.x","article-title":"Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission","volume":"48","author":"Yang","year":"2007","journal-title":"Epilepsia"},{"issue":"1\u20132","key":"10.1016\/j.schres.2017.06.027_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(01)00188-8","article-title":"A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia","volume":"55","author":"Zhang","year":"2002","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2017.06.027_bb0295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pscychresns.2010.03.007","article-title":"The role of hippocampus dysfunction in deficient memory encoding and positive symptoms in schizophrenia","volume":"183","author":"Zierhut","year":"2010","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.schres.2017.06.027_bb0300","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/seiz.2000.0504","article-title":"Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents","volume":"10","author":"Zona","year":"2001","journal-title":"Seizure"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417303663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T15:54:53Z","timestamp":1535730893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417303663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":60,"alternative-id":["S0920996417303663"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.06.027","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}